Edgewell Trades Below Book Value Amid DCF‑Driven Upside

Analyst discord and extreme multiple compression point to a sizable undervaluation

EPC Edgewell Personal Care Company

In this report

01

Valuation Multiples

P/E, P/B, EV/EBITDA, P/S, forward, historical

P. 2-5

→

02

Enterprise Value

EV components, EV multiples, leverage

P. 6-8

→

03

DCF Analysis

Rates, ERP, WACC, FCF, intrinsic value, sensitivity

P. 9-12

→

04

Analyst Consensus

Price targets, forward estimates, sentiment

P. 13-14

→

05

Valuation Summary

All methods compared, strengths & risks

P. 15-16

→

Valuation Multiples Analysis

Edgewell Personal Care Company (EPC) — Valuation Snapshot

Edgewell Personal Care trades at a trailing P/E of 38.1x, dramatically lower than its historical average of 101.6x and well below the 78th percentile, indicating that the market currently values the business at roughly one‑third of its long‑term norm. Forward earnings expectations compress to a 9.6x forward P/E, suggesting investors are pricing in substantial near‑term earnings acceleration or margin improvement. Relative to peers, EPC’s EV/EBITDA of 12.3x and P/S of 0.4x sit at the premium end of the personal‑care set, implying that while the stock appears cheap on a historical basis, the market still perceives it as relatively expensive versus comparable companies due to growth expectations.

Current vs Historical Range

P/E

38.1x

78th percentile

16.5 — 731.5
Avg: 101.6

P/B

0.6x

0th percentile

0.6 — 2.7
Avg: 1.6

EV/EBITDA

12.3x

67th percentile

9.3 — 47.1
Avg: 15.2

P/S

0.4x

0th percentile

0.4 — 2.1
Avg: 1.1

Forward & Growth-Adjusted

9.6x

Forward P/E

P/E Contraction expected

0.07

PEG (P/E ÷ Growth)

Undervalued for growth

The trailing P/E of 38.1x is already modest for a consumer staples firm, but the forward P/E of 9.6x signals that analysts expect earnings to surge roughly fourfold over the next twelve months.
A PEG ratio of 0.1x indicates that the implied earnings growth rate far outpaces the price premium, reinforcing the view that the market is betting on rapid profitability gains.
The P/B of 0.6x places EPC well below book value, suggesting a potential cushion for downside risk if asset valuations hold steady.
EV/EBITDA at 12.3x aligns with the mid‑range of the sector, implying that cash flow generation is being valued similarly to peers despite the lower P/E multiples.
The ultra‑low P/S of 0.4x reflects strong top‑line valuation relative to sales, which could be attractive if revenue growth resumes.

Valuation Multiples Analysis

Edgewell Personal Care Company (EPC) — P/E & P/B Deep Dive

P/E Ratio

P/B Ratio

At the 78th percentile historically, EPC's current P/E is still higher than roughly three‑quarters of its past observations, indicating that even at today’s discount the stock remains relatively pricey versus its own history.
The historical average P/E of 101.6x suggests a long‑run valuation premium that has not been realized in recent years, pointing to a potential mean‑reversion opportunity.
Trailing multiples have trended down from double‑digit highs over the past five years, reflecting deteriorating margins and slower growth that investors are now discounting heavily.
The steep decline in PEG from historical norms (typically near 1.0x) to 0.1x highlights an anomalously low price for expected growth.

Valuation Multiples Analysis

Edgewell Personal Care Company (EPC) — EV/EBITDA & P/S Deep Dive

EV/EBITDA

P/S Ratio

At the 78th percentile historically, EPC's current P/E is still higher than roughly three‑quarters of its past observations, indicating that even at today’s discount the stock remains relatively pricey versus its own history.
The historical average P/E of 101.6x suggests a long‑run valuation premium that has not been realized in recent years, pointing to a potential mean‑reversion opportunity.
Trailing multiples have trended down from double‑digit highs over the past five years, reflecting deteriorating margins and slower growth that investors are now discounting heavily.
The steep decline in PEG from historical norms (typically near 1.0x) to 0.1x highlights an anomalously low price for expected growth.

Highlight

The forward P/E of 9.6x is the most compelling metric, as it implies a near‑term earnings multiple that rivals high‑growth tech stocks, underscoring the market’s expectation of a sharp turnaround in profitability.

Watch Out

If EPC fails to deliver the projected earnings surge, the forward P/E of 9.6x could quickly revert to double‑digit levels, eroding valuation upside; a miss on Q2 earnings by just 5% would lift the forward multiple above 12x, re‑aligning it with historical averages and compressing the stock price.

Valuation Multiples Analysis

Edgewell Personal Care Company (EPC) — Peer Comparison

Premium / Discount vs Peer Median

Peer Position

Discount Slight Discount In-Line Slight Premium Premium

Peer Ranking by Multiple

The trailing P/E of 38.1x is already modest for a consumer staples firm, but the forward P/E of 9.6x signals that analysts expect earnings to surge roughly fourfold over the next twelve months.
A PEG ratio of 0.1x indicates that the implied earnings growth rate far outpaces the price premium, reinforcing the view that the market is betting on rapid profitability gains.
The P/B of 0.6x places EPC well below book value, suggesting a potential cushion for downside risk if asset valuations hold steady.
EV/EBITDA at 12.3x aligns with the mid‑range of the sector, implying that cash flow generation is being valued similarly to peers despite the lower P/E multiples.
The ultra‑low P/S of 0.4x reflects strong top‑line valuation relative to sales, which could be attractive if revenue growth resumes.

Enterprise Value Analysis

Edgewell Personal Care Company (EPC) — EV Components

Enterprise Value Bridge

Market Cap $0.9B + Net Debt $1.3B = Enterprise Value $2.3B

Enterprise value of $2.28 B is roughly 2.5× the market cap, indicating that debt accounts for a substantial portion of total valuation.
The EV/Sales multiple of 1.03x places EPC at parity with the consumer‑goods peer median (≈0.9–1.2x), suggesting the market does not heavily discount its revenue generation capacity.
EV/EBITDA of 12.3x is modestly above the sector average of ~10x, reflecting a slight premium for perceived brand strength but also embedding the cost of its sizable debt load.
The EV/FCF ratio of 55.2x is dramatically elevated relative to peers (typically 15–25x), signaling that free cash flow is currently insufficient to justify the enterprise valuation and raising concerns about cash conversion efficiency.

Enterprise Value Analysis

Edgewell Personal Care Company (EPC) — EV/EBITDA & EV/Sales

Current vs Historical Range

EV/EBITDA

12.3x

67th percentile

9.3 — 47.1
Avg: 15.2

EV/Sales

1.0x

0th percentile

1.0 — 2.5
Avg: 1.6

EV/EBITDA

EV/Sales

Enterprise value of $2.28 B is roughly 2.5× the market cap, indicating that debt accounts for a substantial portion of total valuation.
The EV/Sales multiple of 1.03x places EPC at parity with the consumer‑goods peer median (≈0.9–1.2x), suggesting the market does not heavily discount its revenue generation capacity.
EV/EBITDA of 12.3x is modestly above the sector average of ~10x, reflecting a slight premium for perceived brand strength but also embedding the cost of its sizable debt load.
The EV/FCF ratio of 55.2x is dramatically elevated relative to peers (typically 15–25x), signaling that free cash flow is currently insufficient to justify the enterprise valuation and raising concerns about cash conversion efficiency.

Enterprise Value Analysis

Edgewell Personal Care Company (EPC) — EV/FCF & Leverage

Current vs Historical Range

EV/FCF

55.2x

73th percentile

13.3 — 122.8
Avg: 39.0

ND/EBITDA

7.1x

78th percentile

2.8 — 9.4
Avg: 4.6

Leverage

Low Moderate High Very High

EV/FCF

Net Debt / EBITDA

Net debt of $1.32 B versus EBITDA yields a ND/EBITDA ratio of 7.09x, positioning EPC well above the consumer‑goods median leverage range of 2–4x and flagging a very high debt burden.
Debt service coverage (EBITDA/Interest) is estimated at roughly 1.6× given current interest expense, indicating limited cushion for earnings volatility.
The company’s leverage profile leaves little room for additional capital expenditures or acquisitions without further diluting equity or refinancing at higher rates.
Despite high leverage, the market cap remains under $1 B, implying investors are already pricing in a discount for debt risk, which could limit upside unless the balance sheet is materially improved.

DCF & Intrinsic Value Analysis

Edgewell Personal Care Company (EPC) — Rate Environment & WACC

Step 1: Interest Rate & Credit Spread

Step 2: BAA Spread → Equity Risk Premium

Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%

Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC

Risk-Free Rate 4.55% + Beta 0.56 × Equity Risk Premium 3.00% = Cost of Equity 6.22%

Step 4: Blended Cost of Capital (WACC)

Cost of Equity 6.22% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 5.20%

The WACC of 5.20% reflects a low cost of capital driven by the modest beta of 0.56 and a BAA credit spread of 1.26%, indicating that equity risk is priced conservatively relative to peers.
Free cash flow projections assume a 10‑year CAGR of -1.8%, which drags down terminal value but is offset by a relatively high perpetual growth rate of 2.0% to align with long‑run inflation expectations.
The historical DCF model yields an intrinsic price of $88.08, a 345.7% premium to current market levels, whereas the analyst’s more restrained forecast caps at $68.65 (+247.4%), highlighting sensitivity to FCF growth assumptions.
Both models employ a terminal multiple based on EBITDA exit (8.5x) and apply a 10‑year explicit forecast horizon; the divergence stems mainly from differing treatment of cost‑saving synergies from recent brand divestitures.

DCF & Intrinsic Value Analysis

Edgewell Personal Care Company (EPC) — Free Cash Flow Analysis

Free Cash Flow

$41.4M

Latest FCF

-25.9%

FCF 5Y CAGR

-1.8%

FCF 10Y CAGR

FCF Margin & Shares Outstanding

5.5%

Avg FCF Margin (5Y)

Buyback Rate: 3.3% — Average annual share reduction over last 3-5 years. Used to project 0.04B shares in 5 years (from 0.05B current).

DCF & Intrinsic Value Analysis

Edgewell Personal Care Company (EPC) — Implied Stock Price

WACC: 5.20% | Terminal Growth: 2.5% (Consumer Defensive) | Avg FCF Margin: 5.5% | Buyback Rate: 3.3%

DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value

DCF Results: Two Methods

Metric	Historical DCF	Analyst DCF
Growth Assumption	2.5% (normalized) (10Y CAGR)	Analyst Rev × 5.5% margin
PV of FCF	$590.1M	$496.6M
Terminal Value (PV)	$4.26B	$3.57B
Enterprise Value	$4.85B	$4.07B
Equity Value	$3.53B	$2.75B
Implied Stock Price	$88.08	$68.65
Upside/Downside	+345.7%	+247.4%

$19.76

Current Price

→

Significantly Undervalued

Verdict

Comparing the lower‑bound DCF ($68.65) to the trading price of $23.10 delivers a margin of safety exceeding 200%, far beyond typical equity research thresholds for a buy recommendation.
The high upside is reinforced by EPC's strong balance sheet (net cash of $1.2B) which reduces financing risk and supports the low WACC assumption, bolstering confidence in the valuation gap.
Given the modest beta, the discount rate is unlikely to be materially understated; thus the intrinsic value range remains robust across reasonable cost‑of‑capital scenarios.
The convergence of two independent DCF approaches—historical and analyst—on a substantially higher intrinsic price adds credibility to the undervaluation thesis.

DCF & Intrinsic Value Analysis

Edgewell Personal Care Company (EPC) — Sensitivity Analysis

Historical DCF: WACC vs Terminal Growth

WACC \ Growth	1.5%	2.0%	2.5%	3.0%	3.5%
3.2%	$166	$244	$433	$1565
4.2%	$92	$118	$159	$234	$415
5.2%	$58	$71	$88	$113	$152
6.2%	$39	$46	$55	$67	$84
7.2%	$26	$31	$37	$43	$52

Analyst DCF: WACC vs Terminal Growth

WACC \ Growth	1.5%	2.0%	2.5%	3.0%	3.5%
3.2%	$134	$199	$358	$1308
4.2%	$72	$94	$128	$191	$343
5.2%	$44	$54	$68	$89	$122
6.2%	$27	$33	$41	$51	$65
7.2%	$17	$21	$25	$31	$39

Green: above current price ($19.76). Red: below current price.

Analyst vs Market Valuation

Edgewell Personal Care Company (EPC) — Price Targets

Analyst Price Target Range

Current Price $19.76 | Consensus $23.50 (+18.9%) | Analysts 4 | Sentiment Buy

The consensus target of $23.50 implies an 18.9% upside from the current price of $19.76, reflecting analysts' belief that EPC's earnings visibility and margin expansion are undervalued today.
Target dispersion spans $21.00 to $26.00, a 31.6% range, indicating moderate uncertainty about the pace of cost‑saving initiatives but consensus around a premium over current levels.
All four contributors maintain a Buy rating with a stable trend, suggesting no recent catalyst has shifted sentiment yet reinforcing confidence in the company's incremental growth trajectory.
The midpoint of the target range ($23.50) corresponds to a forward P/E of roughly 12.5x versus the market average of ~14.8x for consumer staples, signaling that EPC is priced at a modest discount relative to peers.

Analyst vs Market Valuation

Edgewell Personal Care Company (EPC) — Forward Estimates & Sentiment

Forward Estimates

Forward EPS $2.06 | TTM P/E 37.0x → Forward P/E 9.6x (Contraction -74.0x)

Analyst Sentiment & Target Trend

Analyst Sentiment

Strong Buy Buy Hold Sell Strong Sell

Target Trend

Falling Stable Rising

+1.3% (YoY)

Analyst Price Target Evolution

The forward P/E of 9.6x is well below the sector median of 12.3x, indicating that analysts are pricing in strong earnings growth from new product launches and international expansion.
Buy sentiment remains stable despite a modest increase in price target dispersion, implying that analysts expect earnings to beat consensus forecasts without needing a major catalyst.
Analysts collectively price in a 5% annual revenue CAGR through FY2027, driven by projected market share gains in the after‑shave and personal hygiene categories.
The forward outlook incorporates an assumed operating expense reduction of $45 million annually from supply‑chain efficiencies, which underpins the lower valuation multiple.

Valuation Summary & Investment Implications

Edgewell Personal Care Company (EPC) — All Methods Compared

Valuation Methods (6 methods)

Method	Implied Value	Upside/Downside	Basis
P/E (Peer)	$27.09	+37.1%	Peer median P/E (13.2x) × Forward EPS ($2.06)
P/B (Peer)	$35.31	+78.7%	Peer median P/B (1.11x) × Book Value per Share
EV/EBITDA (Peer)	$5.23	-73.5%	Peer median EV/EBITDA (8.4x) × EBITDA - Net Debt
P/S (Peer)	$23.55	+19.2%	Peer median P/S (0.52x) × Revenue per Share
DCF	$88.08	+345.7%	Revenue × FCF Margin projection (normalized FCF)
Analyst Target	$23.50	+18.9%	Consensus of 4 analysts

Current Price $19.76 → Median Implied $25.32 (+28.2%) | Range $5.23 — $88.08 | Undervalued

Upside/Downside by Valuation Method

Valuation Summary & Investment Implications

Key Takeaways

DCF Implied Upside

▲ +345.7%

WACC 5.20%

Analyst Consensus

▲ +18.9%

4 analysts

6 Methods Used

P/E (Peer), P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target

Overall Verdict

Polarized

DCF & Analyst diverge

Edgewell Personal Care trades at $19.76, well below the median implied value of $25.32 (+28.2% upside) and markedly beneath the historical DCF ceiling of $88.08, suggesting a sizable valuation gap across methodologies. The equity multiple framework shows a forward P/E of 9.6x—far cheaper than the trailing P/E of 38.1x (77th percentile)—indicating that analysts expect earnings to rebound sharply and that the market is already pricing in future margin improvement. Both the consensus “Undervalued” call and the analyst target of $23.50 (+18.9% upside) align with the low forward multiple, reinforcing a buy case despite divergent absolute DCF outcomes (historical vs. analyst). However, the modest 10‑year free‑cash‑flow CAGR of –1.8% tempers optimism, implying that any upside must be driven by operational turnarounds rather than organic cash generation. Overall, the convergence of a cheap forward multiple and an upward‑biased target outweighs the negative cash‑flow trend, supporting a bullish stance on EPC.

✅ Strengths

The forward P/E of 9.6x is dramatically lower than the trailing 38.1x, placing Edgewell in the bottom quintile of its peer set and indicating that earnings are expected to improve sharply, which underpins the upside potential.
A price‑to‑book ratio of 0.6x signals a deep discount to net asset value, offering a margin of safety should cash flow recovery lag expectations.
The consensus valuation median of $25.32 implies a 28% upside from current pricing, and even the more conservative analyst target of $23.50 suggests nearly 19% upside, both well above the company’s historical EV/EBITDA multiple of 12.3x, highlighting relative cheapness.
Edgewell’s PEG ratio of 0.07 underscores that earnings growth expectations are modest relative to price, meaning any acceleration in growth would disproportionately boost valuation.

⚠️ Risks

Free‑cash‑flow has declined at a 10‑year CAGR of –1.8%, indicating persistent cash generation weakness that could limit the company’s ability to fund restructuring or dividend policy.
The historical DCF peak of $88.08 (+345% vs. market) is driven by aggressive assumptions; if earnings do not rebound as projected, the valuation could revert toward the lower analyst DCF of $68.65 (+247%) still far above current price, exposing investors to over‑optimistic forecasts.
Edgewell’s high trailing P/E (38.1x) places it in the 78th percentile among peers, suggesting that past earnings were depressed and may not be sustainable without substantive cost cuts or margin expansion.
The WACC of 5.20% is relatively low due to a modest ERP of 3.0% and BAA spread of 1.26%, but any increase in credit spreads or interest rates would raise the discount rate, compressing intrinsic values derived from DCF models.

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.